Efficacy of Alirocumab for Thin-cap fibroatheroma in patients with coronary artery disease estImated by optical coherence tomography trial. - ALTAIR trial

Kobe University Graduate School of Medicine0 个研究点目标入组 24 人开始时间: 2017年10月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Exclusion criteria are follows; 1: Patients who have been treated previously with at least one dose of any anti-PCSK9 monoclonal antibody 2: Patients had uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) between the time of PCI and randomization visit 3: Patients with LDL-C <70 mg/dL 4: Known hypersensitivity to alirocumab or rosuvastatin 5: Known history of hemorrhagic stroke 6: Currently under treatment for cancer 7: Patients on lipoprotein apheresis 8: Patients with severe liver or renal dysfunction 9: All contraindications to rosuvastatin as displayed in the respective national product labeling for these treatments 10: All contraindications to alirocumab as displayed in the respective national product labeling for these treatments 11: Pregnant or breast-feeding women 12: Considered by the investigator as inappropriate for this study for any reason

发起方

Kobe University Graduate School of Medicine